基于BEST-CLI与PREVENT III事后比较的下肢静脉旁路治疗慢性肢体威胁性缺血当代结局
本研究通过事后比较BEST-CLI(2014-2019)与PREVENT III(2001-2003)两项多中心前瞻性随机对照试验中接受下肢腹股沟下静脉旁路的CLTI患者,评估近二十年来旁路结局的变化。共纳入2114例患者(BEST-CLI 710例,PREVENT III 1404例),主要终点为1年MALE或死亡复合终点。结果显示BEST-CLI组1年MALE或死亡发生率显著低于PREVENT III组(21.0% vs 37.8%;调整HR 0.50;95%CI 0.40-0.62;P<.0001),围手术期MACE和MALE也显著降低。
要点
- 近二十年来CLTI下肢静脉旁路术后1年MALE或死亡风险显著下降(调整HR 0.50)。
- BEST-CLI组1年大再次干预率低于PREVENT III组(7.2% vs 18.4%)。
- 围手术期MACE和MALE在BEST-CLI组均显著低于PREVENT III组。
核心结论
- 过去二十年中,CLTI患者下肢腹股沟下静脉旁路术后结局显著改善,可能反映心血管风险管理、手术技术和术后护理的广泛进步。
研究设计与样本
- 事后比较分析,纳入BEST-CLI(2014-2019)和PREVENT III(2001-2003)两项多中心前瞻性随机对照试验中接受下肢腹股沟下静脉旁路的CLTI患者,共2114例(BEST-CLI 710例,PREVENT III 1404例)。
- 平均年龄67.9±11.0岁,女性占32.8%。
- 主要终点为1年MALE或死亡复合终点;次要终点包括围手术期(30天)MACE和MALE。
- 采用多变量Cox和 logistic 回归模型分别分析1年和30天结局,并使用倾向性评分方法进行验证性分析。
主要发现
- BEST-CLI组1年MALE或死亡发生率为21.0%,PREVENT III组为37.8%(调整HR 0.50;95%CI 0.40-0.62;P<.0001), predefined亚组和倾向性评分验证分析结果一致。
- BEST-CLI组1年大再次干预率(新旁路、手术翻修、血栓切除或移植物闭塞的血管内干预)为7.2%,PREVENT III组为18.4%(调整HR 0.40;95%CI 0.28-0.57;P<.0001);任何再次干预率相似(25.8% vs 29.3%;调整HR 0.90;95%CI 0.72-1.14;P=.39)。
- 围手术期MACE在BEST-CLI组为4.1%,PREVENT III组为7.8%(调整OR 0.47;95%CI 0.28-0.79;P=.005)。
- 围手术期MALE在BEST-CLI组为2.7%,PREVENT III组为6.3%(调整OR 0.44;95%CI 0.24-0.82;P=.009)。
临床怎么用
- 对于适合静脉旁路的CLTI患者,当代静脉旁路手术的1年肢体相关结局和围手术期安全性均优于历史对照,支持在合适患者中继续安全有效地开展静脉旁路。
- 围手术期和1年MACE、MALE的降低提示应重视并优化心血管风险管理、手术技术和术后护理。
局限性
- 本研究为事后比较分析,非随机对照比较,尽管采用多变量回归和倾向性评分方法,仍可能存在未测量混杂。
- 两项试验开展时间相隔较长(2001-2003 vs 2014-2019),期间治疗策略和患者特征可能发生变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BEST-CLI (Best Endovascular vs Best Surgical Therapy in Patients with Chronic Limb-Threatening Ischemia [CLTI]) demonstrated the superiority of single-segment great saphenous vein bypass over endovascular treatment for patients with CLTI who were candidates for both treatment strategies. However, with the rise of endovascular techniques and the subsequent decrease in the number of vein bypass procedures being performed, concerns have emerged regarding the continued ability to perform surgical bypass safely and effectively. This study aimed to evaluate whether outcomes after lower extremity infrainguinal vein bypass for CLTI have changed over the past two decades by comparing data from two major randomized controlled trials: BEST-CLI and PREVENT III (Project or Ex-Vivo vein graft Engineering via Transfection III). METHODS: This post hoc comparative analysis included patients with CLTI who underwent lower extremity infrainguinal vein bypass in the multicenter, prospective BEST-CLI (2014-2019) and PREVENT III (2001-2003) trials. The primary outcome was a composite of major adverse limb event (MALE) or death at 1 year. Secondary outcomes included perioperative (30-day) rates of major adverse cardiovascular event (MACE) and MALE. Multivariable Cox and logistic regression models were used for 1-year and 30-day outcomes, respectively, to compare outcomes between the two cohorts; confirmatory analyses were conducted using propensity score methods. RESULTS: In total, 2114 patients underwent infrainguinal vein bypass for CLTI (710 BEST-CLI and 1404 PREVENT III). The mean patient age was 67.9 ± 11.0 years; 32.8% were female. Patients in BEST-CLI had higher use rates of aspirin, statins, and single segment great saphenous vein conduit. The primary end point of 1-year MALE or death was lower in BEST-CLI (21.0%) compared with PREVENT III (37.8%) (adjusted hazard ratio [HR], 0.50; 95% confidence interval [CI], 0.40-0.62; P < .0001)-this observation was consistent across predefined subgroups and in confirmatory analyses using propensity score methods. Major reinterventions (new bypass, surgical revision, thrombectomy, or endovascular intervention for graft occlusion) at 1 year were also lower in BEST-CLI (7.2% vs 18.4%; adjusted HR, 0.40; 95% CI, 0.28-0.57; P < .0001), although rates of any reinterventions were similar (25.8% vs 29.3%; adjusted HR, 0.90; 95% CI, 0.72-1.14; P = .39). Perioperative major cardiovascular and limb events were significantly lower in BEST-CLI: MACE (4.1% vs 7.8%; adjusted OR 0.47; 95% CI, 0.28-0.79; P = .005) and MALE (2.7% vs 6.3%; adjusted OR 0.44; 95% CI, 0.24-0.82; P = .009). CONCLUSIONS: Over the past two decades, outcomes after lower extremity infrainguinal vein bypass for CLTI have improved significantly. These advances likely reflect a combination of broad improvements in cardiovascular risk management, surgical techniques, and postoperative care for CLTI patients.
引用
- Hussain MA, Khan AA, Menard MT, et al. Contemporary outcomes of lower extremity vein bypass for chronic limb-threatening ischemia based on a post hoc comparison of the BEST-CLI and PREVENT III multicenter prospective randomized controlled trials. J Vasc Surg. 2025. PMID: 41317973. doi:10.1016/j.jvs.2025.08.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。